Ironwood Pharmaceuticals, Inc. - Class A
Here’s whether Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.16% over 10 days); RSI 58 — healthy momentum range; strong 1-year return of +302.8%; 3-month momentum positive (+20.4%); rising volume confirms the move (1.19x 30d avg). Currently 25.4% off its 52-week high. Score: +8/7.
IRWD is in a confirmed uptrend, trading above both its 50-day ($3.97) and 200-day ($3.79) moving averages. An RSI of 57.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +302.8% compares to +20.4% for SPY (beat the market by 282.4%). The current 25.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.